![Scott Bratman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Lisa Alderson | F | - |
Adela, Inc.
![]() Adela, Inc. Finance/Rental/LeasingFinance Adela, Inc. is a company that is developing technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). The company is based in Branford, CT. The company's genome-wide methylome enrichment platform captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions. Adela's approach to MRD testing is tissue agnostic, eliminating the burden of acquiring a tumor sample. The CEO of the company is Scott Bratman. | 2 anni |
Andrew ElBardissi | M | 42 |
Adela, Inc.
![]() Adela, Inc. Finance/Rental/LeasingFinance Adela, Inc. is a company that is developing technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). The company is based in Branford, CT. The company's genome-wide methylome enrichment platform captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions. Adela's approach to MRD testing is tissue agnostic, eliminating the burden of acquiring a tumor sample. The CEO of the company is Scott Bratman. | - |
David Scheer | M | - |
Adela, Inc.
![]() Adela, Inc. Finance/Rental/LeasingFinance Adela, Inc. is a company that is developing technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). The company is based in Branford, CT. The company's genome-wide methylome enrichment platform captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions. Adela's approach to MRD testing is tissue agnostic, eliminating the burden of acquiring a tumor sample. The CEO of the company is Scott Bratman. | - |
Maneesh Jain | M | - |
Adela, Inc.
![]() Adela, Inc. Finance/Rental/LeasingFinance Adela, Inc. is a company that is developing technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). The company is based in Branford, CT. The company's genome-wide methylome enrichment platform captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions. Adela's approach to MRD testing is tissue agnostic, eliminating the burden of acquiring a tumor sample. The CEO of the company is Scott Bratman. | - |
Alan Williams | M | - |
Adela, Inc.
![]() Adela, Inc. Finance/Rental/LeasingFinance Adela, Inc. is a company that is developing technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). The company is based in Branford, CT. The company's genome-wide methylome enrichment platform captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions. Adela's approach to MRD testing is tissue agnostic, eliminating the burden of acquiring a tumor sample. The CEO of the company is Scott Bratman. | 1 anni |
Grafico relazionale
Relazione in diverse aziende
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 5 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Scott Bratman
- Contatti personali